A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy

A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy

For estrogen receptor (ER)-negative breast cancer patients, paclitaxel (P), doxorubicin (A) and cyclophosphamide (C) neoadjuvant chemotherapy (NAC) is the standard therapeutic regimen. Pathologic complete response (pCR) and residual disease (RD) are common surrogate measures of chemosensitivity. Aft...

Full description

Bibliographic Details
Main Authors: Yanhua Chen, Hao Cai, Wannan Chen, Qingzhou Guan, Jun He, Zheng Guo, Jing Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Molecular Biosciences
Subjects:
breast cancer
neoadjuvant chemotherapy
pathological complete response
extreme resistance
relative expression ordering
Online Access:https://www.frontiersin.org/article/10.3389/fmolb.2020.00034/full

Internet

https://www.frontiersin.org/article/10.3389/fmolb.2020.00034/full

Similar Items